Pathophysiology and management of low high-density lipoprotein cholesterol (Q33652024)

28 July 2017

1 reference

title

Pathophysiology and management of low high-density lipoprotein cholesterol (English)

1 reference

28 July 2017

0 references

1 reference

Rader DJ

1

1 reference

PubMed ID

10357571

28 July 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

American Journal of Cardiology

28 July 2017

1 reference

28 July 2017

83

1 reference

28 July 2017

9B

1 reference

28 July 2017

22F-24F

1 reference

Familial hyper-alpha-lipoproteinemia: Studies in eighteen kindreds

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900210-6

Plasma high density lipoproteins. Metabolism and relationship to atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900210-6

The "best" of cholesterols, the "worst" of cholesterols: a tale of two receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900210-6

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900210-6

Intravenous Injection of Rabbit Apolipoprotein A-I Inhibits the Progression of Atherosclerosis in Cholesterol-Fed Rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900210-6

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900210-6

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900210-6

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900210-6

Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-densi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900210-6

Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900210-6

Effects of intravenous infusion of lipid-free apo A-I in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900210-6

10.1016/S0002-9149(99)00210-6

7 January 2021

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10357571